Medical breakthroughs are quickly being accessed through a ground-breaking initiative known as the IDAP, designed to provide support to manufacturers and innovators with all-encompassing collaborative support
This dynamic ecosystem, known as the integrated development and approval process (IDAP), fosters rapid advancements, discoveries, and cutting-edge technologies, fueling the evolution of healthcare and improving patient outcomes.
These medical breakthroughs operate through customized scientific guidance and accelerated patient impact.
This new initiative is expected to go into effect in the second half of 2023, will be jointly run by the MHRA, NICE, and a group of other stakeholders, including the devolved administrations.
The main objective of this innovation is to advance cutting-edge technologies and solutions within the National Health Service (NHS) by reducing ambiguity in the pathway to medical accessibility by introducing groundbreaking technologies to patients, thereby revolutionizing health results.
IDAP initiative ignites progress in safe and effective solutions
The UK government has announced its encouragement for medical technology innovators, regardless of commercial or non-commercial status and whether they are based in the UK or internationally, to register for further information.
This initiative precedes a planned pilot launch in 2023, and the insights gained from the pilot will be utilized by IDAP partners to develop a visible framework supporting innovators in obtaining regulatory approval, health technology assessment decisions, and patient access in the NHS.
The UK as a centre for medical innovation
Chief Science and Innovation Officer for the MHRA, Dr. Marc Bailey, spoke on the exciting news:
“The new IDAP will demonstrate how the UK regulator, health technology assessment and the healthcare system are working together to deliver safe, effective, and earlier innovative medical products to patients, establishing the UK as a centre for medical innovation.”
deliver safe, effective, and earlier innovative medical products to patients, establishing the UK as a centre for medical innovation
The IDAP partners will leverage the lessons learned from the pilot to create an end-to-end framework that assists innovators in generating the necessary evidence for regulatory approval, health technology assessments, and patient access in the NHS.
A transparent and seamless procedure will be provided by this complete framework, enabling innovators to produce the evidence required for regulatory approval, health technology assessments, and eventually, patient access inside the NHS.
Mark Chapman, the Interim Director of Medical Technology and Digital Evaluations at NICE, shared his insights:
“We look forward to working with industry to continue the acceleration of our evaluations and with the MHRA to align our work for the benefit of patients.”
